Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Xlife Sciences AG
  6. News
  7. Summary
    XLS   CH0461929603

XLIFE SCIENCES AG

(XLS)
  Report
Delayed Swiss Exchange  -  11:31 2022-10-06 am EDT
33.60 CHF   -4.00%
09/28Xlife Sciences' H1 Loss Widen, Revenue Jumps in First Report Since SIX Swiss Transfer
MT
09/28Xlife Sciences with pleasing progress in the first half of 2022
EQ
09/26Project company Laxxon Medical achieves major milestone
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Project company Xsight Optics successfully participates in start-up competition ? prize money finances relevant R&D project

05/16/2022 | 01:08am EDT

Xlife Sciences AG / Key word(s): Miscellaneous
Project company Xsight Optics successfully participates in start-up competition ? prize money finances relevant R&D project

16.05.2022 / 07:05


Xsight Optics, based in Jena (Germany), a project company of Xlife Sciences AG (SIX: XLS), has successfully participated in this year's StartUp competition ?get started 2gether? organized by the Thuringia Research and Technology Association and the Thuringia Ministry of Economics: The company won funding for a relevant new research and development project, and was also awarded the audience prize.

Xsight Optics' vision is to expand human-centered, digital care. To this end, the company is developing a portable optical sensor with which medical staff in hospitals and care facilities can, for example, record the heart rate, oxygen saturation, temperature, and respiratory rate of patients from a safe distance without contact (and transfer them directly to an already existing Documentation system).

This mobile sensor derives these health parameters from several image properties through a clever combination of optical technology, microelectronics, and AI-supported algorithms. Central to this is secure and reliable imaging software. The awarded prize money of EUR 80,000 will enable Xsight Optis to finance a corresponding R&D project with the Intelligent Systems Department of the Institute for Applied Building Research Weimar.

Oliver R. Baumann, CEO of Xlife Sciences, comments: ?We warmly congratulate CEO Maria Nisser and CSO Jan Sperrhake of our project company Xsight Optics for their doubly successful pitch at the renowned Thuringian StartUp funding award ?get started 2gether?. The funding thus achieved for the interdisciplinary research and development project with the experts in computer vision and data analysis from the Institute for Applied Building Research Weimar is a relevant milestone for Xsight Optics' endeavor to expand human-centered, digital care.?

 

Financial calendar

Ordinary General Assembly 2022            June 20, 2022

2022 Half-Year Results                              September 28, 2022

 

Contact

Information for journalists: IRF Reputation AG, Valentin Handschin, handschin@irf-reputation.ch

Information for investors: Xlife Sciences AG, Dennis Lennartz, dennis.lennartz@xlifesciences.ch

Xlife Sciences AG
 
Talacker 35
8001 Zürich
Telefon: 0041 44 385 84 60
ISIN: CH0461929603
WKN: A2PK6Z
Börsen: SIX Swiss Exchange  

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements.



End of Media Release


Language: English
Company: Xlife Sciences AG
Talacker 35
8001 Zürich
Switzerland
Phone: +41 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
Valor: A2PK6Z
Listed: SIX Swiss Exchange
EQS News ID: 1352665

 
End of News EQS News Service

1352665  16.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1352665&application_name=news&site_id=zonebourse_sftp

© EQS 2022
All news about XLIFE SCIENCES AG
09/28Xlife Sciences' H1 Loss Widen, Revenue Jumps in First Report Since SIX Swiss Transfer
MT
09/28Xlife Sciences with pleasing progress in the first half of 2022
EQ
09/26Project company Laxxon Medical achieves major milestone
EQ
09/21Xlife Sciences Adopts Annual ESG Reporting To Boost Transparency
MT
09/21Xlife Sciences strengthens sustainability activities with ESG strategy
EQ
09/15Baader Bank initiates research coverage on Xlife Sciences
EQ
08/22Intron Health initiates research coverage of Xlife Sciences
EQ
07/04FUSE-AI supports German pharmacies in digitization
EQ
05/16Project company Xsight Optics successfully participates in start-up competition ? prize..
EQ
05/09Xlife Sciences : First Valuation Report confirms substancial potential of the project port..
EQ
More news
Financials
Sales 2020 0,40 M 0,40 M 0,40 M
Net income 2020 21,5 M 21,8 M 21,8 M
Net Debt 2020 47,7 M 48,4 M 48,4 M
P/E ratio 2020 -
Yield 2020 -
Capitalization 185 M 187 M 188 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 6
Free-Float 45,8%
Chart XLIFE SCIENCES AG
Duration : Period :
Xlife Sciences AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XLIFE SCIENCES AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Managers and Directors
Oliver R. Baumann Chief Executive Officer
Carl von Halem Chief Financial Officer
Bernhard Scholz Chairman-Supervisory Board
Frank Ploger Chief Scientific Officer
Christian Faber Member-Supervisory Board & Head-Legal & Compliance
Sector and Competitors
1st jan.Capi. (M$)
XLIFE SCIENCES AG0.00%188
MODERNA, INC.-50.54%49 142
LONZA GROUP AG-33.72%38 001
IQVIA HOLDINGS INC.-31.78%35 901
SEAGEN INC.-11.47%25 244
ALNYLAM PHARMACEUTICALS, INC.18.67%24 128